Paracrine regulation of osteoclast formation and activity: milestones in discovery.

The molecular and physiological mechanisms of control of osteoclast formation and activity have been explained with the discovery of three members of the Tumour Necrosis Factor superfamily. Receptor activator of NF-kappaB ligand (RANKL) is the type II membrane protein in cells of the osteoblastic lineage which interacts with its receptor, RANK, on hemopoietic precursors to promote osteoclast formation and maintain their viability and activity. The process is further regulated by the decoy receptor, osteoprotegerin (OPG), also produced by stromal/osteoblastic cells, and which binds to RANKL to prevent RANKL stimulation of osteoclast formation. These discoveries fulfilled predictions that came from more than 20 years of research in bone cell biology in predominantly rodent systems. The hypothesis that the osteoblast lineage directed osteoclast function introduced the concept of intercellular communication in bone. It needed new methods to be developed to test it, and there were many who contributed to this. With a number of identifiable milestones from the early 1980s on, a highly convincing case was made for the existence of what turned out to be RANKL and RANK. As it happened, OPG came first, and the background biological information was so instructive that it was obvious that OPG would lead to the final answer. By that stage the necessary methods were all in place, and in a short time all the key molecular regulators were identified. Ultimate proof of their physiological importance came from genetic experiments in mice.

[1]  N. Udagawa,et al.  Cloning of an osteoblastic cell line involved in the formation of osteoclast‐like cells , 1990, Journal of cellular physiology.

[2]  K Yano,et al.  Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. , 1998, Biochemical and biophysical research communications.

[3]  N. Udagawa,et al.  Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures. , 1998, Biochemical and biophysical research communications.

[4]  R. W. Young CELL PROLIFERATION AND SPECIALIZATION DURING ENDOCHONDRAL OSTEOGENESIS IN YOUNG RATS , 1962, The Journal of cell biology.

[5]  I. Morita,et al.  Prostaglandins promote osteoclast-like cell formation by a mechanism involving cyclic adenosine 3',5'-monophosphate in mouse bone marrow cell cultures. , 1989 .

[6]  A. Wetterwald,et al.  Detection of transcripts for the receptor for macrophage colony-stimulating factor, c-fms, in murine osteoclasts. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[7]  T. Martin,et al.  Osteoblastic cells are involved in osteoclast formation. , 1988, Endocrinology.

[8]  D. Lacey,et al.  Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.

[9]  S. Nishikawa,et al.  The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene , 1990, Nature.

[10]  H. Rasmussen,et al.  The physiological and cellular basis of metabolic bone disease , 1973 .

[11]  T. Chambers,et al.  Effect of prostaglandins E1, E2, and F2 alpha on osteoclast formation in mouse bone marrow cultures. , 1991, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[12]  E H Burger,et al.  In vitro formation of osteoclasts from long-term cultures of bone marrow mononuclear phagocytes , 1982, The Journal of experimental medicine.

[13]  R. Baron Molecular mechanisms of bone resorption: therapeutic implications. , 1996, Revue du rhumatisme.

[14]  J. Saklatvala,et al.  Osteoblasts mediate interleukin 1 stimulation of bone resorption by rat osteoclasts , 1986, The Journal of experimental medicine.

[15]  T. Martin,et al.  Modulation of osteoclast differentiation. , 1992, Endocrine reviews.

[16]  T J Chambers,et al.  The pathobiology of the osteoclast. , 1985, Journal of clinical pathology.

[17]  J. Loutit,et al.  Longevity of osteoclasts in radiation chimaeras of osteopetrotic beige and normal mice. , 1982, British journal of experimental pathology.

[18]  M. Holtrop,et al.  The Ultrastructure of the Osteoclast and its Functional Implications , 1977, Clinical orthopaedics and related research.

[19]  T. Taniguchi,et al.  T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. , 2000, Nature.

[20]  N. Udagawa,et al.  Role of prostaglandins in interleukin‐1‐induced bone resorption in mice in vitro , 1991, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[21]  Sheila J. Jones,et al.  Osteoclast-like cell formation and its regulation by osteotropic hormones in mouse bone marrow cultures. , 1988, Endocrinology.

[22]  D. Simmons,et al.  Investigation of cell lineage in bone using a chimaera of chick and quail embryonic tissue , 1975, Nature.

[23]  M. Horton,et al.  Human macrophage colony‐stimulating factor inhibits bone resorption by osteoclasts disaggregated from rat bone , 1988, Journal of cellular physiology.

[24]  S. Mochizuki,et al.  Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. , 1997, Biochemical and biophysical research communications.

[25]  T. Martin,et al.  Interleukin (IL)-6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoblastic cells but not on osteoclast progenitors , 1995, The Journal of experimental medicine.

[26]  H. Okamura,et al.  Interleukin 18 inhibits osteoclast formation via T cell production of granulocyte macrophage colony-stimulating factor. , 1998, The Journal of clinical investigation.

[27]  G. Nicholson,et al.  Long‐term culture of disaggregated rat osteoclasts: Inhibition of bone resorption and reduction of osteoclast‐like cell number by calcitonin and PTHrP[107‐139] , 1993, Journal of cellular physiology.

[28]  G. Vaes Cellular biology and biochemical mechanism of bone resorption. A review of recent developments on the formation, activation, and mode of action of osteoclasts. , 1988, Clinical orthopaedics and related research.

[29]  T. Martin,et al.  Role of osteoblasts in hormonal control of bone resorption - a hypothesis. , 1982, Calcified tissue international.

[30]  K Yano,et al.  Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[31]  G. Hattersley,et al.  Generation of osteoclastic function in mouse bone marrow cultures: multinuclearity and tartrate-resistant acid phosphatase are unreliable markers for osteoclastic differentiation. , 1989, Endocrinology.

[32]  T. Chambers,et al.  Calcitonin alters behaviour of isolated osteoclasts , 1982, The Journal of pathology.

[33]  S. Mochizuki,et al.  Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. , 1998, Endocrinology.

[34]  W. Dougall,et al.  RANK is essential for osteoclast and lymph node development. , 1999, Genes & development.

[35]  H. Nakauchi,et al.  Generation of osteoclasts from isolated hematopoietic progenitor cells. , 1989, Blood.

[36]  Terry Farrah,et al.  The TNF receptor superfamily of cellular and viral proteins: Activation, costimulation, and death , 1994, Cell.

[37]  T. Martin,et al.  Localization of RANKL (receptor activator of NF kappa B ligand) mRNA and protein in skeletal and extraskeletal tissues. , 1999, Bone.

[38]  R. Dubose,et al.  A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function , 1997, Nature.

[39]  T. Martin,et al.  Prostaglandin effects on bone and role in cancer hypercalcaemia , 1979 .

[40]  T. Martin,et al.  A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro. , 1998, Endocrinology.

[41]  D. Dempster,et al.  Perspectives: Protons and osteoclasts , 1990 .

[42]  M. Cecchini,et al.  Macrophage colony stimulating factor restores in vivo bone resorption in the op/op osteopetrotic mouse. , 1990, Endocrinology.

[43]  N. Udagawa,et al.  Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[44]  E H Burger,et al.  Cells of bone: proliferation, differentiation, and hormonal regulation. , 1986, Physiological reviews.

[45]  E. Wagner,et al.  c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. , 1994, Science.

[46]  P. Nijweide,et al.  In vitro osteoclast generation from different bone marrow fractions, including a highly enriched haematopoietic stem cell population , 1986, Nature.

[47]  D. G. Walker Bone resorption restored in osteopetrotic mice by transplants of normal bone marrow and spleen cells , 1975, Science.

[48]  G Shimamoto,et al.  Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density , 1997, Cell.

[49]  T. Martin,et al.  Parathyroid hormone (PTH)-related protein is a potent stimulator of osteoclast-like multinucleated cell formation to the same extent as PTH in mouse marrow cultures. , 1989, Endocrinology.

[50]  S. Morony,et al.  osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. , 1998, Genes & development.

[51]  R. Baron,et al.  Dissociation between bone resorption and bone formation in osteopenic transgenic mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[52]  G. Rodan,et al.  Biphasic effects of transforming growth factor-beta on the production of osteoclast-like cells in mouse bone marrow cultures: the role of prostaglandins in the generation of these cells. , 1990, Endocrinology.

[53]  P. McSheehy,et al.  Osteoblast-like cells in the presence of parathyroid hormone release soluble factor that stimulates osteoclastic bone resorption. , 1986, Endocrinology.

[54]  T. Martin,et al.  Induction of calcitonin receptors by 1 alpha, 25-dihydroxyvitamin D3 in osteoclast-like multinucleated cells formed from mouse bone marrow cells. , 1988, Endocrinology.

[55]  P. Sexton,et al.  Abundant calcitonin receptors in isolated rat osteoclasts. Biochemical and autoradiographic characterization. , 1986, The Journal of clinical investigation.

[56]  N. Udagawa,et al.  Deficiency of osteoclasts in osteopetrotic mice is due to a defect in the local microenvironment provided by osteoblastic cells. , 1991, Endocrinology.

[57]  P. McSheehy,et al.  Osteoblastic cells mediate osteoclastic responsiveness to parathyroid hormone. , 1986, Endocrinology.

[58]  R. Steinman,et al.  TRANCE (Tumor Necrosis Factor [TNF]-related Activation-induced Cytokine), a New TNF Family Member Predominantly Expressed in T cells, Is a Dendritic Cell–specific Survival Factor , 1997, The Journal of experimental medicine.

[59]  S. Teitelbaum,et al.  Partial characterization of a parathyroid hormone-stimulated resorption factor(s) from osteoblast-like cells. , 1989, Endocrinology.

[60]  J. Ericsson,et al.  The osteoclast: review of ultrastructure, origin, and structure-function relationship. , 1976, Clinical orthopaedics and related research.

[61]  T. Chambers The cellular basis of bone resorption. , 1980, Clinical orthopaedics and related research.

[62]  S. Morony,et al.  OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis , 1999, Nature.

[63]  T. Martin,et al.  Mechanisms by which cells of the osteoblast lineage control osteoclast formation and activity , 1994, Journal of cellular biochemistry.

[64]  H. Fleisch,et al.  Constitutive expression of osteoclast-stimulating activity by normal clonal osteoblast-like cells: effects of parathyroid hormone and 1,25-dihydroxyvitamin D3. , 1992, Endocrinology.

[65]  T. Martin,et al.  The bone marrow-derived stromal cell lines MC3T3-G2/PA6 and ST2 support osteoclast-like cell differentiation in cocultures with mouse spleen cells. , 1989, Endocrinology.

[66]  P. Nijweide,et al.  Osteoclast formation from mononuclear phagocytes: role of bone-forming cells , 1984, The Journal of cell biology.

[67]  G. Mundy,et al.  Tumor necrosis factors alpha and beta induce osteoblastic cells to stimulate osteoclastic bone resorption. , 1987, Journal of immunology.

[68]  M. Noble,et al.  Generation of osteoclast-inductive and osteoclastogenic cell lines from the H-2KbtsA58 transgenic mouse. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[69]  E. Jimi,et al.  Osteoclast function is activated by osteoblastic cells through a mechanism involving cell-to-cell contact. , 1996, Endocrinology.

[70]  E. A. Tonna Osteoclasts and the aging skeleton: A cytological, cytochemical and autoradiographic study , 1960, The Anatomical record.

[71]  T. Martin,et al.  Cell biology of bone. , 1988, Bailliere's clinical endocrinology and metabolism.

[72]  H. Schneider,et al.  Structural requirements for the action of parathyroid hormone‐related protein (PTHrP) on bone resorption by isolated osteoclasts , 1991, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[73]  J. Hock,et al.  Colony-stimulating factors regulate the development of multinucleated osteoclasts from recently replicated cells in vitro. , 1987, The Journal of clinical investigation.

[74]  D. Eyre,et al.  Isolation of a murine osteoclast colony-stimulating factor. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[75]  M. Lee,et al.  Identification and characterization of osteoclast progenitors by clonal analysis of hematopoietic cells. , 1992, Blood.

[76]  Brian R. Wong,et al.  TRANCE Is a Novel Ligand of the Tumor Necrosis Factor Receptor Family That Activates c-Jun N-terminal Kinase in T Cells* , 1997, The Journal of Biological Chemistry.

[77]  E. Jimi,et al.  Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function. , 1999, Journal of immunology.